GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » Price-to-Owner-Earnings

POINT Biopharma Global (POINT Biopharma Global) Price-to-Owner-Earnings : (As of May. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is POINT Biopharma Global Price-to-Owner-Earnings?

As of today (2024-05-25), POINT Biopharma Global's share price is $12.50. POINT Biopharma Global does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for POINT Biopharma Global's Price-to-Owner-Earnings or its related term are showing as below:


PNT's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.37
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-25), POINT Biopharma Global's share price is $12.50. POINT Biopharma Global's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $1.10. Therefore, POINT Biopharma Global's PE Ratio for today is 11.36.

As of today (2024-05-25), POINT Biopharma Global's share price is $12.50. POINT Biopharma Global's EPS without NRI for the trailing twelve months (TTM) ended in was $0.97. Therefore, POINT Biopharma Global's PE Ratio without NRI for today is 12.89.

During the past 3 years, POINT Biopharma Global's highest PE Ratio without NRI was 14.49. The lowest was 6.66. And the median was 9.14.


POINT Biopharma Global Price-to-Owner-Earnings Historical Data

The historical data trend for POINT Biopharma Global's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

POINT Biopharma Global Price-to-Owner-Earnings Chart

POINT Biopharma Global Annual Data
Trend Dec20 Dec21 Dec22
Price-to-Owner-Earnings
- - -

POINT Biopharma Global Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of POINT Biopharma Global's Price-to-Owner-Earnings

For the Biotechnology subindustry, POINT Biopharma Global's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


POINT Biopharma Global's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, POINT Biopharma Global's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where POINT Biopharma Global's Price-to-Owner-Earnings falls into.



POINT Biopharma Global Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

POINT Biopharma Global's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=12.50/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


POINT Biopharma Global  (NAS:PNT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


POINT Biopharma Global Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of POINT Biopharma Global's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


POINT Biopharma Global (POINT Biopharma Global) Business Description

Traded in Other Exchanges
N/A
Address
4850 West 78th Street, Indianapolis, IN, USA, 46268
POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Joe A. Mccann director, officer: Chief Executive Officer 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Rajesh Malik director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Gerald L. Hogue director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472